MA50526A - Cocristaux, compositions pharmaceutiques de ceux-ci, et méthodes de traitement les impliquant - Google Patents
Cocristaux, compositions pharmaceutiques de ceux-ci, et méthodes de traitement les impliquantInfo
- Publication number
- MA50526A MA50526A MA050526A MA50526A MA50526A MA 50526 A MA50526 A MA 50526A MA 050526 A MA050526 A MA 050526A MA 50526 A MA50526 A MA 50526A MA 50526 A MA50526 A MA 50526A
- Authority
- MA
- Morocco
- Prior art keywords
- cocrystals
- methods
- pharmaceutical compositions
- treatment involving
- involving
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/265—Citric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762580501P | 2017-11-02 | 2017-11-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA50526A true MA50526A (fr) | 2020-09-09 |
Family
ID=64572453
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA050526A MA50526A (fr) | 2017-11-02 | 2018-11-02 | Cocristaux, compositions pharmaceutiques de ceux-ci, et méthodes de traitement les impliquant |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US11345677B2 (fr) |
| EP (1) | EP3704101A1 (fr) |
| JP (3) | JP7335877B2 (fr) |
| KR (1) | KR20200095480A (fr) |
| CN (2) | CN111527076B (fr) |
| AU (2) | AU2018360827B2 (fr) |
| BR (1) | BR112020008598A2 (fr) |
| CA (1) | CA3081535A1 (fr) |
| EA (1) | EA202091112A1 (fr) |
| IL (2) | IL274123B2 (fr) |
| MA (1) | MA50526A (fr) |
| MX (2) | MX2020004513A (fr) |
| PH (1) | PH12020550462A1 (fr) |
| SG (1) | SG11202003612VA (fr) |
| TW (2) | TWI839131B (fr) |
| UA (1) | UA127380C2 (fr) |
| WO (1) | WO2019090059A1 (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200085832A1 (en) * | 2019-11-22 | 2020-03-19 | Agios Pharmaceuticals, Inc. | Deuterated analogs of an organic compound |
| WO2022036033A2 (fr) | 2020-08-12 | 2022-02-17 | Servier Pharmaceuticals, Llc | Formes à l'état solide d'un composé organique |
| US20230346789A1 (en) | 2022-03-31 | 2023-11-02 | Msd International Gmbh | Methods of treating enhancing brain tumors using combination therapy |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ609957A (en) * | 2010-11-01 | 2015-08-28 | Celgene Avilomics Res Inc | Heterocyclic compounds and uses thereof |
| US9579324B2 (en) * | 2013-07-11 | 2017-02-28 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
| WO2015003360A2 (fr) * | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Composés thérapeutiquement actifs et leurs méthodes d'utilisation |
-
2018
- 2018-11-02 IL IL274123A patent/IL274123B2/en unknown
- 2018-11-02 CN CN201880079771.0A patent/CN111527076B/zh active Active
- 2018-11-02 EA EA202091112A patent/EA202091112A1/ru unknown
- 2018-11-02 TW TW112106677A patent/TWI839131B/zh active
- 2018-11-02 BR BR112020008598-7A patent/BR112020008598A2/pt unknown
- 2018-11-02 US US16/760,520 patent/US11345677B2/en active Active
- 2018-11-02 TW TW107139079A patent/TWI796377B/zh active
- 2018-11-02 UA UAA202003279A patent/UA127380C2/uk unknown
- 2018-11-02 WO PCT/US2018/058930 patent/WO2019090059A1/fr unknown
- 2018-11-02 CN CN202410230044.7A patent/CN118359585A/zh active Pending
- 2018-11-02 AU AU2018360827A patent/AU2018360827B2/en active Active
- 2018-11-02 EP EP18812419.2A patent/EP3704101A1/fr active Pending
- 2018-11-02 JP JP2020524501A patent/JP7335877B2/ja active Active
- 2018-11-02 CA CA3081535A patent/CA3081535A1/fr active Pending
- 2018-11-02 IL IL305426A patent/IL305426B2/en unknown
- 2018-11-02 KR KR1020207015661A patent/KR20200095480A/ko active IP Right Grant
- 2018-11-02 MX MX2020004513A patent/MX2020004513A/es unknown
- 2018-11-02 MA MA050526A patent/MA50526A/fr unknown
- 2018-11-02 SG SG11202003612VA patent/SG11202003612VA/en unknown
-
2020
- 2020-04-22 PH PH12020550462A patent/PH12020550462A1/en unknown
- 2020-07-13 MX MX2022014792A patent/MX2022014792A/es unknown
-
2022
- 2022-04-19 US US17/723,666 patent/US11851417B2/en active Active
-
2023
- 2023-04-24 JP JP2023070786A patent/JP7499377B2/ja active Active
- 2023-11-08 US US18/504,859 patent/US20240343705A1/en active Pending
-
2024
- 2024-05-14 AU AU2024203186A patent/AU2024203186A1/en active Pending
- 2024-06-03 JP JP2024090124A patent/JP2024113028A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA46102A (fr) | Composés de tétracycline et méthodes de traitement | |
| MA43135A (fr) | Compositions et méthodes pour le du traitement du cancer | |
| MA46481A (fr) | Compositions d'oligonucléotides et méthodes associées | |
| MA41028A (fr) | Méthodes et formulations pour le traitement de pathologies oculaires vasculaires | |
| MA52257A (fr) | Compositions pharmaceutiques comprenant blautia et leur administration orale | |
| MA43172A (fr) | Compositions pharmaceutiques et méthodes d'inhibition d'indolamine 2,3-dioxygénase et leurs indications | |
| MA46742A (fr) | Composition pharmaceutique, méthodes de traitement et leurs utilisations | |
| EA201691582A1 (ru) | Новые фармацевтические препараты | |
| MA41119A (fr) | Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique | |
| MA56212A (fr) | Compositions et méthodes de traitement du cancer | |
| MA48730A (fr) | Compositions et méthodes de traitement de synucléinopathies | |
| MA52118A (fr) | Nouveaux composés et compositions pharmaceutiques de ceux-ci destinés au traitement de la fibrose | |
| MA52790A (fr) | Compositions et méthodes de traitement de la thrombopénie immune | |
| MA45675A (fr) | Méthodes et compositions permettant le traitement du cancer | |
| IL269901B (en) | Pharmaceutical compounds and methods of treating cardiovascular diseases | |
| MA54716A (fr) | Réduction de la viscosité de formulations pharmaceutiques | |
| BR112017007748A2 (pt) | composição farmacêutica, agente antialérgico, composição alimentar, composição cosmética, uso de um extrato, e, método para prevenir ou tratar uma doença alérgica | |
| MA50526A (fr) | Cocristaux, compositions pharmaceutiques de ceux-ci, et méthodes de traitement les impliquant | |
| MA41120A (fr) | Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci | |
| FR3022139B1 (fr) | Nouvelles compositions pour le traitement des rougeurs cutanees et de la rosacee | |
| MA40687A (fr) | Méthodes et compositions de traitement de malformation vasculaire | |
| EP3468540A4 (fr) | Compositions pharmaceutiques et méthodes de traitement du cancer | |
| ES2982382T3 (es) | Composiciones farmacéuticas de liberación modificada de huperzina y procedimientos de utilización de las mismas | |
| FR3044227B1 (fr) | Derives aminophosphiniques pour la prevention et le traitement des douleurs oculaires | |
| EP3525787A4 (fr) | Méthodes de traitement et compositions pharmaceutiques utilisant bcn057 ou bcn512 |